When ASCL1 or POU2F3 Exo‐mRNAs was individually combined with the dual DLL3 Exo‐mRNA/tEV‐mProtein biomarker, the AUC/ROC improved: LS‐SCLC patients from 0.836 to 0.837 with ASCL1, and from 0.836 to 0.886 with POU2F3; ES‐SCLC patients from 0.839 to 0.895 with ASCL1, and from 0.839 to 0.930 with POU2F3 (Figure 5F,G). Here, DLL3 is linked to small cell lung carcinoma.